Week 8 Flashcards
Functions of the skeleton
Mechanical- support and muscle attachment
Protective- for vital organs and marrow
Metabolic- ion homeostasis especially calcium and phosphate
Basic structure of bones
Epiphysis- end part of long bone, initially growing separately form shaft
Diaphysis- shaft or central part of long bone
Metaphysis- wide portion of long bone and regions of bone where growth occurs
Cortical bone- dense and solid and surrounds marrow space (compact, lamellar)
Cancellous (trabecular) bone- bone involved in bone turnover
Articular cartilage
Growth (epiphysial) plate
What is bone made of
Specialised connective tissue
Extracellular matrix which is able to calcify
Collagen fibres
Non collagenous proteins essential to bone function (osteocalcin, osteonectin, osteopontin)
Mineralisation (calcification) occurs with formation of hydroxyapatite crystals (complex of calcium and phosphate crystals). Embedded in bone to give bone structural integrity
Contains several types of cells
Cell types within bone
Osteocytes
Osteoblasts
Osteoclasts
Osteocytes
Deep embedded in calcified bone matrix, have long processes which contact other osteocytes and osteoblasts. Important for regulation of bone turnover
Osteoblasts
Bone forming cells which produce matrix constituents and aid calcification. Collagen and hydroxyapatite
Originate from mesenchymal stem cells (bone marrow stem cells or connective tissue mesenchymal cells)
Classical marker- alkaline phosphatase (regulator of bone mineralisation), osteocalcin (non-collagenous protein)
Osteoclasts
Bone resorbing cells usually found in contact with calcified bone surface- in lacunae
Multinucleated- originate from bone marrow lineage
Produce acid (to resorb mineral) and enzymes (to resorb matrix)
Attachment to bone very important- integrins
Classical markers- carbonic anhydrase, tartrate-resistant acid phosphatase (TRAP), RANK, calcitonin receptor
What is an osteoid
Unmineralised bone tissue
Osteoclasts development
Osteoblast contain RANK ligand (RANKL) and attaches to RANK receptor on osteoclast precursor. Regulated by VIT D, PTH
Then forms a mature osteoclast
Osteoprotegerin OPG, interacts with RANK ligand and prevent osteoclast interaction. Regulated by estrogens
Denosumab- limits production of mature osteoclast by acting as a decoy for RANK ligand receptor process
Bone cells and bone remodelling
Dynamic process
Osteoclast binds to bone surface (integrens)
Resorption
Osteoclast releases acid and enzymes forming resorption pit. Releasing Ca2+/PO4 +collagen
Forms osteoid
Layers of collagen mineralised to form new bone by osteoblasts
The bone remodelling cycle (trabecular bone)
Resting surface
Osteoclast, bone resorption
Osteoblast, reversal phase
Bone formation (osteoid)
Bone formation (osteoid- mineralisation front)
Resting surface
Hope that same amount bone produced as bone resorbed
Osteoporosis
Loss of bone mass (increased risk of fracture)
Increase in bone mass as age increases, reach peak bone mass at 20-30
Osteoblasts dominating osteoclasts, more bone mass
As you get older process reverses osteoclast dominate, bone resorption dominates over formation, bone mass decreases
Bone and calcium homeostasis
Bone - protect vital organs, support muscles, reservoir of calcium. >99% calcium
Soluble calcium- excitable tissue, muscle contraction, nerves, cell adhesion <1%
Calcium homeostasis
GI tract, absorb Ca
Kidney, homeostatically controlling ca release
Bone
Parathyroid hormone PTH
84 amino acid peptide but biological activity in first 34 amino acids (PTH 1-34), half life 8 mins
Normal adult reference range =1.6-6.9 pmol/L
Binds to cell membrane G protein coupled receptors
Causes signalling inside cell. Mainly in kidney and osteoblasts
Hypocalcaemia
Calcium sensitive receptors in parathyroid
Increased PTH secretion
Increase bone resorption,
Kidney: increase urinary phosphate, decrease urinary calcium, increase 1,25D3 production (active from vitD)
Intestine: increase calcium and phosphate absorption
Increase serum calcium
Negative feedback mechanism
Vitamin D
Best used to refer to precursor form 25-hydroxyvitamin D3 (25D3)
Numbers after name reflect origin, Vit D2 of plant origin, Vit D3 of animal origin
Numbers before name reflect changes (hydroxylations) in Vit D that change its biological activity (1,25D3) binds to intracellular vitamin D receptor VDR, active from of vit D made in kidneys
25D3 is easier and cheaper to measure so used most in hospitals
<50nmol/L [20ng/ml] is insufficient
Where do we get vit D from
UV radiation mainly - skin (7-dehydrocholesterol)- Vit d3
Diet—vitamin D3
Into blood , into liver (25D3), into kidney which activates 25D3, stimulated by PTH to produce 1,25D3
Calcitonin
Produced by thyroid c-cells (parafollicular- which dont produce thyroid hormones)
Calcitonin released in hypercalcaemia, inhibits bone resorption (by direct effect on osteoclasts), no ca released
Not essential to life
Hypercalcaemia
Thyroid increases calcitonin production, decreases bone resorption
Kidney: decrease urinary phos, increase urinary calcium, decreased 1,25D3 production
Intestine: decrease calcium and phosphate absorption
Decrease serum calcium
Fibroblast growth factor 23 (FGF23)
Phosphate regulating hormone
Produced by bone cells (osteocytes and maybe osteoblasts)
Released in response to high serum PO4
Increase renal excretion of PO4 and suppresses renal synthesis of active vit D
Main inducer of FGF23 appears to be 1,25D3
Hyperphosphataemia
Osteocytes sense change and produce more FGF23
Increase FGF23 in bone, suppresses 1,25D3
Kidney: increase in urinary phos, decrease urinary calcium
Dominant effects on kidney reverses high phosphate
Decreasing serum phosphate
Primary hyperparathyroidism
Raised serum PTH:
Parathyroid tumour (usually benign adenoma)
Causes hypercalcaemia and low serum phosphate
Loss of negative feedback. Treatment is surgery, can be given calcimimetics
Clinical features: lethargy/confusion, thirst/polyuria, renal stones, constipation, pancreatitis, joint pain, fracture, depression, hypertension
Calcimimetics
Drugs that are allosteric activators of calcium sensing receptor. So enhancing signalling and decreasing PTH release